Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

79 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-16

Study Completion Date

2018-11-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study investigates the effect of 3 days of twice daily treatment of two different doses of RPL554 (a phosphodiesterase \[PDE\]3/4 inhibitor) or placebo, each administered in addition to once daily tiotropium/olodaterol (Respimat) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will receive each of the three treatment combinations in a randomized sequence using a crossover design

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of RPL554 in Addition to Tiotropium in COPD Patients

NCT03028142

Chronic Obstructive Pulmonary Disease Moderate

COMPLETED PHASE2

Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

NCT03937479

COPD

COMPLETED PHASE2

The Effects of RPL554 on Top of Standard COPD Reliever Medications

NCT02542254

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE2

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

NCT00239473

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE3

Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD

NCT02683109

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

RPL554 is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) which are known to have a role in modulating the inflammatory airway response in respiratory diseases, including COPD. PDE3 inhibitors act as bronchodilators whilst PDE4 inhibitors have anti-inflammatory properties and there is also evidence to suggest that combined inhibition of PDE3 and PDE4 can have additive or synergistic anti-inflammatory and bronchodilator. The two doses of RPL554 (1.5 mg and 6 mg)have been selected based on the results from prior studies investigating single and multiple ascending doses in healthy subjects, single doses in asthmatics, single/multiple ascending doses in COPD patients, and 3 days of dosing in COPD patients. These doses were demonstrated to be both effective as a bronchodilator and well tolerated.

The purpose of the study is to investigate if RPL554 has an additive bronchodilator effect when administered in combination with a commonly used anticholinergic/β-agonist combination medication, tiotropium/olodaterol (Respimat), in this patient population measured by the peak forced expiratory volume in one second (FEV1), and forced vital capacity (FVC).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

The nebulizer cup will be obscured so the contents are not visible to the subject and the blinded study staff.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1.5 mg RPL554 and tiotropium/olodaterol

1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily

Group Type EXPERIMENTAL

RPL554 Suspension

Intervention Type DRUG

A PDE3/4 inhibitor

Tiotropium/olodaterol (Respimat)

Intervention Type DRUG

An anticholinergic/β-agonist combination medication

6 mg RPL554 and tiotropium/olodaterol

6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily

Group Type EXPERIMENTAL

RPL554 Suspension

Intervention Type DRUG

A PDE3/4 inhibitor

Tiotropium/olodaterol (Respimat)

Intervention Type DRUG

An anticholinergic/β-agonist combination medication

Placebo and tiotropium/olodaterol

Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

A placebo solution

Tiotropium/olodaterol (Respimat)

Intervention Type DRUG

An anticholinergic/β-agonist combination medication

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RPL554 Suspension

A PDE3/4 inhibitor

Intervention Type DRUG

Placebo

A placebo solution

Intervention Type DRUG

Tiotropium/olodaterol (Respimat)

An anticholinergic/β-agonist combination medication

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent
2. Male or female aged 40 and 80 years
3. For males, not to donate sperm and either be sexually abstinent or use contraception as specified by the protocol. For females, be of non-childbearing potential or use a highly effective form of contraception
4. 12-lead ECG with heart rate between 45 and 90 beats per minute, QTcF ≤450 msec for males, and ≤ 470 msec for females, QRS interval ≤120 msec and no clinically significant abnormality including morphology
5. Screening Holter report with a minimum of 18 hours recording that is able to be evaluated for rhythm analysis showing no abnormality which indicates a significant impairment of patient safety or which may significantly impair interpretation
6. Capable of complying with all study restrictions and procedures including ability to use the study nebulizer and Respimat® correctly.
7. Body mass index (BMI) between 18 and 36 kg/m2 and minimum weight of 45 kg.
8. COPD diagnosis for at least 1 year and clinically stable COPD for 4 week
9. Post-bronchodilator (two puffs of salbutamol/albuterol followed by two puffs of ipratropium) spirometry at Screening:

* Post-bronchodilator FEV1/forced vital capacity (FVC) ratio of ≤0.70
* Post-bronchodilator FEV1 ≥30 % and ≤70% of predicted normal
* Demonstrates ≥150 mL increase from pre-bronchodilator FEV1
10. A chest X-ray showing no abnormalities, which are both clinically significant and unrelated to COPD.

12\. Meet the concomitant medication restrictions and be expected to do so for the rest of the study.

13\. Current and former smokers with smoking history of ≥10 pack years. 14. Capable of withdrawing from long acting bronchodilators for the duration of the study, and short acting bronchodilators for 8 hours prior to dosing.

Exclusion Criteria

1. A history of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation.
2. COPD exacerbation requiring oral or parenteral steroids, or lower respiratory tract infection requiring antibiotics, in the last 3 months
3. A history of one or more hospitalizations for COPD in the last 12 months
4. Intolerance or hypersensitivity to tiotropium, olodaterol, atropine, ipratropium, or RPL554.
5. Evidence of cor pulmonale or clinically significant pulmonary hypertension.
6. Other respiratory disorders
7. Previous lung resection or lung reduction surgery.
8. Use of oral COPD medications, except mucolytics, in the last 3 months
9. Pulmonary rehabilitation, unless such treatment has been stable in the last 4 weeks
10. History of, or reason to believe a patient has, drug or alcohol abuse within the past 5 years.
11. Inability to perform acceptable spirometry or whole body plethysmography
12. Received an experimental drug within 30 days or five half lives, whichever is longer.
13. Patients with uncontrolled disease that the Investigator believes are clinically significant. This includes any hepatic disease, or an alanine aminotransferase or aspartate aminotransferase\>2 x upper limit of normal (ULN).
14. Documented cardiovascular disease: arrhythmias, angina, recent (\<1 year) or suspected myocardial infarction, congestive heart failure, unstable or uncontrolled hypertension, or diagnosis of hypertension in the last 3 months
15. Use of non-selective oral β-blockers.
16. Major surgery (requiring general anesthesia) in the last 6 weeks or will not have fully recovered from surgery, or planned surgery through the end of the study.
17. A disclosed history or one known to the Investigator, of significant non compliance in previous investigational studies or with prescribed medications.
18. Required use of oxygen therapy, even on an occasional basis.
19. Symptomatic prostatic hyperplasia or bladder-neck obstruction or with narrow-angle glaucoma.
20. History of malignancy of any organ system within 5 years, with the exception of localized skin cancers (basal or squamous cell).
21. Clinically significant abnormal values for safety laboratory tests (hematology, biochemistry, virology or urinalysis) as determined by the Investigator
22. Any other reason that the Investigator considers makes the patient unsuitable to participate.

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No